TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05414591
Drug: DWP16001 drug B
Normalized name: INVESTIGATIONAL ANTI-VIRAL DRUGS HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablet, Oral, once daily single dose
Study: NCT04859764
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: intraarticular knee injection of betamethasone and bupivacaine 0.5% (dose is determined by joint size)
Study: NCT05936567
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral; tablet
Study: NCT05703854
Drug: CAR.70/IL15-transduced CB-derived NK cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV (vein)
Study: NCT05703854
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV (vein)
Study: NCT06453265
Drug: Treatment A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cebranopadol, dose determined in Part A
Study: NCT06453265
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone HCl IR 40 mg
Study: NCT06462508
Drug: [18F]F-PSMA-N5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject receive a single intravenous injection of \[18F\]F-PSMA-N5, and undergo PET/CT imaging within the specificed time.
Study: NCT06462508
Drug: [68Ga]Ga-PSMA-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject receive a single intravenous injection of \[68Ga\]Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
Study: NCT06304818
Drug: SCTB14
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCTB14,IV
Study: NCT05586152
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Ophthalmic Solution
Study: NCT05339529
Drug: Thymosin Alpha1, 28A-Glycine-28B-L-Arginine-28C-L-Glutamic Acid-28D-L-Alanine-28E-L-Proline-28F-L-Alanine-28G-L-Asparagine-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin alpha 1, 1.6mg injection hypodermic (I.H), every 12 hours for 5 days at least during the ICU admission. The administration will be terminated any day during the treatment when the patient is deemed as qualified for ICU discharge or dead.
Study: NCT05339529
Drug: Blank control
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blank control
Study: NCT05935787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml / min, for 15 days + Placebo, 2 tablets 2 times a day, for 25 days
Study: NCT05842408
Drug: DA-5212-R
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control drug: DA-5212-R
Study: NCT06213454
Drug: TAP Anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: ultrasound guided TAP block, 133 mg of liposomal bupivacaine and 15 mL of 0.25% bupivacaine deposited into the TAP on each side for a total of two injections
Study: NCT06213454
Drug: Surgeon-Initiated Local Anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 266 mg of liposomal bupivacaine and 30 mL of 0.25% bupivacaine diluted in 130 mL of normal saline (160 mL of solution), 40 mL fascial injection and 40 mL skin injection on either side of the wound
Study: NCT05630547
Drug: SAR443820
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet by oral administration
Study: NCT05694741
Drug: AZD0186
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive AZD0186 orally.
Study: NCT05694741
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo orally.
Study: NCT06367166
Drug: Venarus® (diosmin and hesperidin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venarus® (diosmin and hesperidin) at a dosage of 1000 mg once daily for 6 months
Study: NCT05289726
Drug: Traditional chinese medicine TDX105
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group Traditional chinese medicine TDX105
Study: NCT05289726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: he control group received placebo granules mixed with dextrin and food coloring
Study: NCT05772013
Drug: Azithromycin Pill
Normalized name: azithromycin Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take azithromycin according to their standard of care prescription.~If the participant is on the seasonal azithromycin treatment arm, they will only take azithromycin during the winter months (October-March) followed by matched placebo (April-September).
Study: NCT05772013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo tablets will be matched in appearance, taste and smell to the azithromycin tablets.
Study: NCT06533033
Drug: Rapid Release Capsules Melatoni
Normalized name: melatonin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twenty-five will be given melatonin therapy in combination with the conventional treatment.~2 tablets,30 minutes before sleeping once daily for 8 weeks.
Study: NCT06409364
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo tablet,
Study: NCT06265428
Drug: DB-1303/BNT323
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered I.V.
Study: NCT05566223
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day -6 and Day -5: Cyclophosphamide 60 mg/kg/dose as a 2 hour intravenous infusion with Mesna 15 mg/kg/dose, 1st dose prior to Cyclophosphamide infusion then at 3,6,9 and 12 hours later.
Study: NCT05944965
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and placebo (sugar pill) administered 30 mins prior to bed
Study: NCT05688020
Drug: Epinephrine injection
Normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine will be injected as part of the standard injectate used during endoscopic resection.
Study: NCT04866017
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: The chemotherapy regimen for the study treatment was selected at the investigator's discretion and may include one of the following options:~* Cisplatin (50 mg/m²) on days 1 to 5 of each cycle, combined with etoposide (50 mg/m²) on days 1 and 8, both administered intravenously for 2 cycles. Each cycle was 28 days.~* Carboplatin (AUC 2) weekly for 6 weeks, combined with paclitaxel (40-50 mg/m²) weekly for 6 weeks, both administered intravenously.~* Cisplatin (75 mg/m²) combined with pemetrexed (500 mg/m²) on day 1 of each cycle, administered intravenously for 2 cycles. Each cycle was 21 days.~* Carboplatin (AUC 5) combined with pemetrexed (500 mg/m²) on day 1 of each cycle, administered intravenously for 2 cycles. Each cycle was 21 days.~The pemetrexed plus platinum regimen was only for participants with non-squamous histology.
Study: NCT04711889
Drug: Blank control
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blank control
Study: NCT05862090
Drug: RLD2301
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once a day per period.
Study: NCT05862090
Drug: RLD2007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once a day per period.
Study: NCT05824065
Drug: OMA102
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg
Study: NCT05824065
Drug: OMA102
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg
Study: NCT05824065
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMA102 - Placebo
Study: NCT05603468
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid group: after the surgery of rotator cuff repair under arthroscopy, 1mL prednisone (MSD) + 2mL sodium hyaluronate (biochemical Industry Co., Ltd.) was injected under arthroscopy.
Study: NCT05603468
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT06356389
Drug: JX11502MA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT06356389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT05698238
Drug: CA9hu-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humanized monoclonal antibody to human carbonic anhydrase IX
Study: NCT06157008
Drug: General Anesthetics
Normalized name: GENERAL ANESTHETICS,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthetics used in spinal cord electrical stimulator insertion surgery
Study: NCT06367205
Drug: Goal-Directed Fluid Therapy (GDFT)
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine will be administered intravenously at a rate of 0.06 µg/kg/min, followed by the implementation of fluid therapy guided by SVV until reaching our target. In instances where SVV ≤ 13%, indicative of adequate effective circulating blood volume, the fluid infusion rate will be adjusted to 1 ml/kg/h. Conversely, if SVV \> 13%, denoting inadequate effective circulating blood volume, a rapid infusion of 1 ml/kg of crystalloid fluid will be administered over 2 minutes, with subsequent observation of fluid reactivity after a further 2-minute interval. This process is reiterated until SVV ≤ 13% is attained. Should SVV \> 13% recurs during surgery, the aforementioned intervention is repeated.
Study: NCT05662033
Drug: AZD6793
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6793 will be administered orally
Study: NCT05662033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally
Study: NCT04857931
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients meeting all inclusion criteria and no exclusion criteria will be randomly assigned to receive either colchicine (0.5mg once daily), colchicine (0.5mg twice daily) or matched placebo (1:1:1 allocation ratio), in addition to standard of care.
Study: NCT05549401
Drug: CKD-828, D097, D337
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PQ
Study: NCT05900284
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: If randomized to the Placebo arm, a tablet will be administered orally to the study participant twice a day for the initial five days starting on the date of study enrollment. Clinical research coordinators will collect blood and urine samples from study participants in both treatment arms. The blood will be collected at Baseline, Day 1 thru 7, and at hospital discharge or Day 30, whichever occurs first. On Day 2 and Day 5, the blood will be collected at hour-based intervals of 0.5h, 1h, 2h, 4h, 8h, 12h for a pharmacokinetic profile and delivered to the University of Pittsburgh Medical Center Clinical Laboratory for analysis. The remaining blood collection tubes will be delivered to the Clinical Research Biospecimen Core laboratory to be processed, separated into microtubes, and stored at -80°. Urine samples will be collected at Baseline, Day 1, 3, and 5. The urine will be processed, separated into microtubes, and frozen at -80°.
Study: NCT06579066
Drug: Probiotic Blend Capsule
Normalized name: Probiotic Blend Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will administer (probiotics) Linex® one capsule daily orally along with the standard care of therapy for duration of 4 weeks.
Study: NCT06579482
Drug: Aesculus hippocastanum, and associations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination product
Study: NCT05586815
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg every 12 hours orally for at least 7 and up to a maximum of 28 days
Study: NCT05586815
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule without active compound
Study: NCT05410938
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triweekly chemotherapy with bevacizumab versus intraperitoneal chemotherapy without bevacizumab
Study: NCT04542473
Drug: Pancreatic Enzyme
Normalized name: Pancreatic enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: CREON micro 5000
Study: NCT04799626
Drug: biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc
Approvals — FDA: no, EMA: no, PMDA: no
Description: biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc extended infusion time or continuous infusion for 24 hours;Tigecycline changed standard does for treatment.
Study: NCT05718375
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05431075
Drug: Tetracycline tid
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Included in quadruple eradication medication.
Study: NCT05431075
Drug: Tetracycline qid
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Included in quadruple eradication medication.
Study: NCT05536154
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 6: 6mg
Study: NCT05817851
Drug: Vitamin C (Laroscorbine) + Vitamin B1 (Bevitine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: in addition of standard post-CA as the control group, patients will receive an IV high-dose vit-C 50mg/kg infusion every 6 hours, started within the hour after randomization, for 3 days. In addition, all patients will receive intravenous thiamine 200 mg twice a day for 3 days to limit the oxalate production.
Study: NCT05817851
Drug: standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: no intervention Standard IV vit-C supplementation will be allowed for dosages up to 1000 mg a day from day 4 after randomization, as well as thiamin supplementation.
Study: NCT06542536
Drug: Monlunabant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral monlunabant
Study: NCT06542536
Drug: Placebo (monlunabant)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo (monlunabant)
Study: NCT05154682
Drug: Acetaminophen 500Mg Tab
Normalized name: ACETAMINOPHEN 500MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen will be taken every 4 hours for 2 weeks after surgery
Study: NCT05154682
Drug: Naproxen 500 Mg
Normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen will be taken every 12 hours for 2 weeks after surgery
Study: NCT05950334
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered as an IV infusion at a dose of 500 mg/m\^2 on Day -5, Day -4, and Day -3 of the treatment cycle.
Study: NCT04846959
Drug: Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous or Intravenous Injection
Study: NCT05439902
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one placebo capsule per day for 30 days. with identical appearance (color and size) to the experimental drug, composed of microcrystalline cellulose
Study: NCT06260904
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prednisolone 0.75mg/kg/day (a maximum dose of 30mg at baseline) orally
Study: NCT06260904
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 15 mg weekly orally
Study: NCT04851483
Drug: BAY2328065
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid Form, Oral administration.
Study: NCT04851483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo of BAY2328065.
Study: NCT05109091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken BID
Study: NCT04766177
Drug: Bumetanide
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bumetanide 0.5 mg twice daily
Study: NCT04766177
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets twice daily
Study: NCT06265077
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04941040
Drug: Opioid free anesthetics
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive over the 10 minutes prior to induction:~* Acetaminophen 1 gm i.v. infusion in 100ml over 10 minutes.~* Ketorolac 30 mg i.v. infusion in100 ml over 10 minutes.~* Mg SO4 loading dose 30 mg/kg i.v. infusion in 100 ml over 10 minutes.~* Dexmedetomidine loading dose 1 μg/kg i.v. infusion.~* Lidocaine loading dose 1.5 mg/kg i.v. infusion.~* Ketamine loading dose 0.25 mg/kg i.v. infusion.~The weight based doses of dexmedetomidine, lidocaine, ketamine will be prepared on 20 ml syringe and infused over 10 minutes prior to induction. In a dose of 0.1 ml/kg~Then after induction maintenance analgesic infusion will start in a rate that ranges from 0.025 to 0.05 ml/kg/h which is equivalent to:~* Dexmedetomidine 0.25-0.5 μg/kg/h~* Lidocaine 0.375-0.75 mg/kg/h~* Ketamine 0.0625- 0.125 mg/kg/h
Study: NCT04941040
Drug: Opioid Anesthetics
Normalized name: Opioid anesthetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo equivalent to acetaminophen, ketorolac, magnesium sulphate will be infused as 100 ml normal saline each over 10 minutes ,patients will receive fentanyl 2 μg/kg loading dose which will be prepared over 20 ml syringe and infused over 10 minutes prior to induction, Then after induction maintenance of analgesic infusion by fentanyl 0.5-1 μg/kg/h.
Study: NCT04958109
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of Placebo 16 hours
Study: NCT06562361
Drug: [68Ga]Ga-DOTA-Cys-ATH001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target dose of 200MBq \[68Ga\]Ga-DOTA-Cys-ATH001 corresponding to a maximum mass dose of 100 µg, administered as an intravenous bolus dose.
Study: NCT06216054
Drug: LPM3770164 sustained release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: administrated orally
Study: NCT06216054
Drug: LPM3770164 sustained release tablet simulant
Normalized name: STAPHYLOCOCCUS SIMULANS
Approvals — FDA: no, EMA: no, PMDA: no
Description: administrated orally
Study: NCT04861987
Drug: PCS6422 and capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer. Capecitabine is a commonly used oral fluoropyrimidine.
Study: NCT04986176
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT04278625
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen given as part of standard of care.
Study: NCT06102057
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard of care consolidation therapy with durvalumab (fixed dose of 1500 mg q4w) for up to 12 months or until progression of disease, unacceptable toxicity, patient´s wish, or investigator´s decision, whichever comes first.
Study: NCT05844813
Drug: Doxorubicin+Ifosfamide+Anlotinib(AI+A)
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin（PLD） 40mg/㎡ d1, Ifosfamide（I） 1g/㎡ d1-5, Anlotinib（A）10mg d1-14 Q3weeks \* 3 Circles
Study: NCT04952506
Drug: CKD-349 F1 Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1T Single does
Study: NCT04952506
Drug: CKD-349 F2 Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1T Single does
Study: NCT04952506
Drug: D113 Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1T Single does
Study: NCT06319859
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will receive 15 mg heavy bupivacaine with 0.1 ml saline intrathecally
Study: NCT04711915
Drug: 0.1 mg/kg Dimethyltryptamine (DMT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg DMT
Study: NCT04711915
Drug: 0.3 mg/kg Dimethyltryptamine (DMT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg DMT
Study: NCT06624137
Drug: Serotonergic Psychedelic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any serotonergic or classic psychedelic that exhibits mainly Serotonin 2A receptor (5-HT2AR) agonism and is judged to produce subjectively similar effects.
Study: NCT02327754
Drug: Placebo BID, (Oral daily dosing for 28 weeks)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the placebo arm will receive placebo.
Study: NCT05452928
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo either in IV formulation or as tablets identical to valacyclovir tablets.
Study: NCT04791761
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
Study: NCT04791761
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
Study: NCT05831527
Drug: ARMRA™ Bovine Colostrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants have the option to choose between unflavoured ARMRA™ Bovine Colostrum or blood orange flavoured ARMRA™ Bovine Colostrum.~Participants took 2 sachets (1g each) of the product mixed with a cold drink daily for 12 weeks.
Study: NCT06022757
Drug: XNW5004
Approvals — FDA: no, EMA: no, PMDA: no
Description: XNW5004 an EZH2 inhibitor, BID, administered in continuous
Study: NCT06022757
Drug: KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: KEYTRUDA® (pembrolizumab) a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
Study: NCT05003141
Drug: PSB202
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSB202 is an antibody combination product comprised of two full-length monoclonal antibodies, PSB102 and PSB 107, respectively targeting CD20 and CD37. PSB202 is manufactured to work as a single product.